Evidence map›Paper›PMID 40728546›Full record

ArticleMolecular biotechnology2026

Inhibition of GPR75 Alleviates Lipid Metabolism by Activating the AMPK-SIRT1 Signaling Pathway In Vitro and In Vivo.

Junyu Wang, Guishun Sun, Shiwen Li, Xuan He, Rongzhuang Zou, Kunlin Li, Bian Wu

Abstract read
In one paragraph

Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junyu Wang *Department of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Guishun SunDepartment of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Shiwen LiDepartment of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Xuan HeDepartment of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Rongzhuang ZouDepartment of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Kunlin Li *Department of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China.
Bian Wu *Department of Gastrointestinal and Bariatric Metabolic Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jingbi Road, Kunming City, 650032, Yunnan Province, China. 13987172118@163.com.ORCID http://orcid.org/0009-0000-6174-1812

Funding

Kunming Medical University Joint Yunnan Provincial Science and Technology Major Project 202301AY070001-058the Yunnan Provincial Science and Technology Department Major Science and Technology Project 202402AA310006Yunnan Provincial Geriatric Disease Clinical Research Centre and the Yunnan Provincial People's Hospital Open Project for Clinical Medicine Centre 2023YJZX-LN19
6 · The paper itself

Abstract

The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is primarily driven by excessive lipid accumulation and metabolic dysregulation, necessitating a comprehensive investigation into the underlying mechanisms. This study employed an in vitro model, wherein Huh7 cells were induced with a palmitic acid/oleic acid mixture, and an in vivo model involving the provision of a high-fat diet to SD rats for six weeks. Employing techniques such as oil red O staining, immunofluorescence, and Western blotting, we examined lipid synthesis, metabolism, and the associated molecular pathways. The findings indicate that GPR75 overexpression markedly enhances lipid synthesis and impairs lipid metabolism. Conversely, GPR75 knockdown significantly diminished the fluorescence intensity of lipid synthesis factors FASN and SREBP1, concurrently elevating the expression of AMPK and SIRT1 proteins, which culminated in reduced lipid synthesis and improved lipid metabolism. Furthermore, inhibiting the AMPK-SIRT1 pathway following GPR75 knockdown led to a significant reversal of these lipid metabolic alterations. Overall, our study elucidates that GPR75 inhibition may diminish lipid accumulation and enhance lipid metabolism both in vitro and in vivo, primarily through the activation of the AMPK-SIRT1 signaling pathway.

Indexed as

AMP-Activated Protein KinasesLipid MetabolismReceptors, G-Protein-CoupledSignal TransductionSirtuin 1AnimalsCell Line, TumorDiet, High-FatHumansMaleNon-alcoholic Fatty Liver DiseaseRatsRats, Sprague-DawleyAMP-Activated Protein KinasesHCAR2 protein, humanReceptors, G-Protein-CoupledSIRT1 protein, humanSirtuin 1AMPK-SIRT1 pathwayFASNGPR75Lipid accumulationMetabolismSREBP1

Identifiers

PMID40728546
PMCPMC13053379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.